Literature DB >> 24419514

Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantation.

M Sato1, H Nakasone1, K Terasako-Saito1, K Sakamoto1, R Yamazaki1, Y Tanaka1, Y Akahoshi1, H Nakano1, T Ugai1, H Wada1, R Yamasaki1, Y Ishihara1, K Kawamura1, M Ashizawa1, S-i Kimura1, M Kikuchi1, A Tanihara1, J Kanda1, S Kako1, J Nishida1, Y Kanda1.   

Abstract

We previously reported that the baseline C-reactive protein level did not predict infectious events after hematopoietic cell transplantation (HCT). Procalcitonin (PCT) has recently emerged as a powerful biomarker for the early diagnosis of bacterial infection. We evaluated the ability of the baseline PCT level to predict early infectious events after HCT in 79 recipients who received HCT between 2008 and 2012. The high-PCT group (≥ 0.07 ng/mL, n=27) frequently experienced documented infection (DI) (21.2% vs 44.4% at day 30, P=0.038) and bloodstream infection (BSI) (15.4% vs 37.0% at day 30, P=0.035). In a multivariate analysis, however, the baseline PCT level was not significantly associated with DI (HR 2.01, P=0.089) or BSI (HR 2.28, P=0.084). Localized infection, such as anal canal problems, before the start of conditioning was seen in 26 patients. When we stratified the patients according to the presence of elevated PCT and localized infection, the group with elevated PCT and localized infection (n=17) was significantly associated with increased DI (HR 3.40, P=0.0074) and BSI (HR 3.59 P=0.0078) after HCT. A larger prospective observation is warranted to confirm the impact of the baseline PCT level and clinical features on the outcome of HCT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419514     DOI: 10.1038/bmt.2013.217

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  21 in total

1.  Diagnostic performance of procalcitonin for bacteremia in patients with bacterial infection at the emergency department.

Authors:  Chih-Cheng Lai; Che-Kim Tan; Shey-Ying Chen; Cheng-Yi Wang; Wei-Lun Liu; Ching-Cheng Hou; Po-Ren Hsueh
Journal:  J Infect       Date:  2010-10-23       Impact factor: 6.072

2.  One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.

Authors:  K Oshima; T Takahashi; T Mori; T Matsuyama; K Usuki; Y Asano-Mori; F Nakahara; S Okamoto; M Kurokawa; Y Kanda
Journal:  Transpl Infect Dis       Date:  2010-10       Impact factor: 2.228

3.  The clinical role of procalcitonin in hematopoietic SCT.

Authors:  J Koya; Y Nannya; M Ichikawa; M Kurokawa
Journal:  Bone Marrow Transplant       Date:  2012-02-20       Impact factor: 5.483

4.  Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation.

Authors:  Lothar Hambach; Matthias Eder; Elke Dammann; Andreas Schrauder; Karl-Walter Sykora; Christian Dieterich; Philip Kirschner; Jürgen Novotny; Arnold Ganser; Bernd Hertenstein
Journal:  Haematologica       Date:  2002-06       Impact factor: 9.941

5.  Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study.

Authors:  Junya Kanda; Hiroh Saji; Takahiro Fukuda; Takeshi Kobayashi; Koichi Miyamura; Tetsuya Eto; Mineo Kurokawa; Heiwa Kanamori; Takehiko Mori; Michihiro Hidaka; Koji Iwato; Takashi Yoshida; Hisashi Sakamaki; Junji Tanaka; Keisei Kawa; Yasuo Morishima; Ritsuro Suzuki; Yoshiko Atsuta; Yoshinobu Kanda
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

6.  Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases.

Authors:  C A Scirè; L Cavagna; C Perotti; E Bruschi; R Caporali; C Montecucco
Journal:  Clin Exp Rheumatol       Date:  2006 Mar-Apr       Impact factor: 4.473

7.  Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center.

Authors:  Annick Galetto-Lacour; Samuel A Zamora; Alain Gervaix
Journal:  Pediatrics       Date:  2003-11       Impact factor: 7.124

Review 8.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

9.  Are IL-6, IL-10 and PCT plasma concentrations reliable for outcome prediction in severe sepsis? A comparison with APACHE III and SAPS II.

Authors:  C Wunder; O Eichelbrönner; N Roewer
Journal:  Inflamm Res       Date:  2004-03-18       Impact factor: 4.575

10.  In Critically Ill Patients, Serum Procalcitonin Is More Useful in Differentiating between Sepsis and SIRS than CRP, Il-6, or LBP.

Authors:  Iwan A Meynaar; Wouter Droog; Manou Batstra; Rolf Vreede; Paul Herbrink
Journal:  Crit Care Res Pract       Date:  2011-05-15
View more
  3 in total

1.  Clinical utility of procalcitonin in bacterial infections in patients undergoing hematopoietic stem cell transplantation.

Authors:  Amit Bansal; Preethi Jeyaraman; S K Gupta; Nitin Dayal; Rahul Naithani
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients.

Authors:  N Shingai; T Morito; Y Najima; T Kobayashi; N Doki; K Kakihana; K Ohashi; M Ando
Journal:  Bone Marrow Transplant       Date:  2015-08-24       Impact factor: 5.483

3.  Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients.

Authors:  Karin Melanie Cabanillas Stanchi; Manon Queudeville; Carmen Malaval; Judith Feucht; Patrick Schlegel; Markus Dobratz; Christian Seitz; Ingo Müller; Peter Lang; Rupert Handgretinger; Michaela Döring
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-24       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.